News

Sativex is an endocannabinoid modulator made of two actives – THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). It was developed and is manufactured by GW Pharmaceuticals. GW Pharmaceuticals’ marketing partner

The company’s decision is based on an interim analysis data, which according to the members of the Interim Review Committee does not support the continuation of GLPG0259’s development

The reason behind the recalling of drugs is related to the complains of uncharacteristic odor associated with the medication caused by trace amounts of TBA (2,4,6 tribromoanisole). TBA

ERT offers centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes ePRO in multiple modalities across all phases of clinical research.

Under the contract, Trius will receive up to $3m over three years in support of its development efforts. The current contract aims to create antibiotics that kill bacteria

The transaction will be funded by a combination of cash and existing debt financing. Hikma CEO Said Darwazah said through this strategic partnership, Hikma and Unimark will collaborate

Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for RA. ORAL Scan is an ongoing two-year

The Phase 2 trial is designed to investigate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies. In the trial, three patients demonstrated partial response

The QBC STAR measures nine important CBC hematological parameters from venous or capillary blood samples: hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), platelet count, white blood cell count,